Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial.

"Declarations Ethics approval and consent to participateThis study will adhere to the Helsinki Declaration as revised in 2000 and to institutional and national regulations in China [34]. This trial protocol was reviewed and approved by the Ethics Committee of Guangxi Medical University Cancer Hospital [reference number CS2021(74)]. All participants will sign informed consent prior to inclusion in the study. Consent for publicationNot applicable—no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the corresponding author on request. When signing the informed consent, all participants will be informed that the relevant data will be compiled and published after the end of the study. Competing interestsNo sponsors were involved in this study. The authors declare no conflicts of interest relevant to the content of this article. Competing interests No sponsors were involved in this study. The authors declare no conflicts of interest relevant to the content of this article."

"Funding The corresponding author is supported by the Specific Research Project of Guangxi for Research Bases and Talents (GuiKe AD22035057), the National Natural Science Foundation of China (82060510 and 82260569), and the Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumors (Guangxi Medical University) at the Ministry of Education (GKE-ZZ202217 and GKE-ZZ202311). The funders have no role in the design and conduct of the present study; collection, analysis, and interpretation of the data; or writing, review, or approval of the manuscript. The above funds are not directly related to this trial. However, these fundings relate to a wider group of projects and apply to this study."

"Trial registration ClinicalTrials.gov NCT02650271. Registered on January 7, 2016."